Media Coverage
Read how Vistagen’s intention to revolutionize mental health medicine is causing a buzz in the media.
Exclusive Interview: VistaGen CEO Is Passionate About Developing New Treatments for Depression
VistaGen CEO notes broad market potential of ketamine-like AV-101
Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more
Company focus: VistaGen
VistaGen acquires worldwide license of phase 3-ready CNS drug
VistaGen nabs phase 3-ready social anxiety drug from Pherin
Stanford researchers are figuring out how ketamine fights depression — and why the drug has been called 'the most important discovery in half a century'
Ketamine is emerging as a popular treatment for depression. New research suggests the drug acts like an opioid
24 Simple Ideas on How to Change Your Habits and Get More Done Today
